These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23648367)

  • 21. [Immunoglobulin therapy].
    Ogata S; Ishii M
    Nihon Rinsho; 2014 Sep; 72(9):1617-22. PubMed ID: 25518412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Kawasaki disease with corticosteroid.
    Shinohara M; Sone K; Kobayashi T; Kobayashi T; Kosuda T; Okada Y
    J Pediatr; 1996 Sep; 129(3):483-4; author reply 484-5. PubMed ID: 8804350
    [No Abstract]   [Full Text] [Related]  

  • 24. Length of hospital stay with prednisolone or cyclosporine for Kawasaki disease.
    Watanabe Y; Ikeda H; Watanabe T; Onuki Y; Iwaku T
    Pediatr Int; 2023; 65(1):e15673. PubMed ID: 38009989
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Kawasaki disease: corticosteroids revisited.
    Newburger JW
    J Pediatr; 1999 Oct; 135(4):411-3. PubMed ID: 10518072
    [No Abstract]   [Full Text] [Related]  

  • 26. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
    Newburger JW; Sleeper LA; McCrindle BW; Minich LL; Gersony W; Vetter VL; Atz AM; Li JS; Takahashi M; Baker AL; Colan SD; Mitchell PD; Klein GL; Sundel RP;
    N Engl J Med; 2007 Feb; 356(7):663-75. PubMed ID: 17301297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
    Aoyagi R; Hamada H; Sato Y; Suzuki H; Onouchi Y; Ebata R; Nagashima K; Terauchi M; Terai M; Hanaoka H; Hata A;
    BMJ Open; 2015 Dec; 5(12):e009562. PubMed ID: 26628527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What dose of aspirin should be used in the initial treatment of Kawasaki disease?
    Ho LGY; Curtis N
    Arch Dis Child; 2017 Dec; 102(12):1180-1182. PubMed ID: 29066520
    [No Abstract]   [Full Text] [Related]  

  • 29. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
    Yang TJ; Lin MT; Lu CY; Chen JM; Lee PI; Huang LM; Wu MH; Chang LY
    J Microbiol Immunol Infect; 2018 Jun; 51(3):321-331. PubMed ID: 28927685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB; Gauvreau K; Burns JC; Corinaldesi E; Tremoulet AH; Watson VE; Baker A; Fulton DR; Sundel RP; Newburger JW
    J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Steroid pulse therapy].
    Miura M
    Nihon Rinsho; 2014 Sep; 72(9):1631-5. PubMed ID: 25518414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent developments and controversies in Kawasaki disease.
    Guzman-Cottrill JA; Shulman ST
    Minerva Pediatr; 2004 Feb; 56(1):51-61. PubMed ID: 15249914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT
    Clin Pediatr (Phila); 2002 Oct; 41(8):597-601. PubMed ID: 12403377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of clinical characteristics of Kawasaki syndrome and risk factors for coronary artery abnormalities among children in Denmark.
    Patel A; Holman RC; Callinan LS; Sreenivasan N; Schonberger LB; Fischer TK; Belay ED
    Acta Paediatr; 2013 Apr; 102(4):385-90. PubMed ID: 23278838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of glucocorticoids in Kawasaki disease.
    Miura M
    Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kawasaki disease: effect of treatment on coronary artery involvement.
    Kato H; Koike S; Yokoyama T
    Pediatrics; 1979 Feb; 63(2):175-9. PubMed ID: 440805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucocutaneous lymph node syndrome in Calabar--a case report.
    Ikpatt NW; Ibia EO
    East Afr Med J; 1989 Nov; 66(11):776-81. PubMed ID: 2606022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS; Durán DG; Peracaula CS; Iznardi CR; Tardío JO
    An Pediatr (Barc); 2010 Nov; 73(5):268-71. PubMed ID: 20678974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.
    O'connor MJ; Saulsbury FT
    Clin Pediatr (Phila); 2007 May; 46(4):345-8. PubMed ID: 17475994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kawasaki disease. Involution of giant coronary aneurysms after prolonged anti-inflammatory treatment.
    Atik E; Foronda A; Bustamante LN
    Arq Bras Cardiol; 2003 Sep; 81(3):265-72. PubMed ID: 14649251
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.